Are preclinical drug studies becoming less replicable at a rapid
rate?
"Phase II [clinical drug trial] success rates for new development
projects have fallen from 28% (2006–2007) to 18% (2008–2009)"
The most common reported cause for failure is lack of efficacy of the
drug.
http://www.nature.com/nrd/journal/v10/n5/full/nrd3439.html
The Google+ URL for this post was
https://plus.google.com/+MatthewBrett/posts/F9b27HJiykN